Affordable Access

Access to the full text

Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan

  • Ueno, Fumiaki1
  • Matsui, Toshiyuki2
  • Matsumoto, Takayuki3
  • Matsuoka, Katsuyoshi4
  • Watanabe, Mamoru5
  • Hibi, Toshifumi4
  • 1 Ofuna Chuo Hospital, Kanagawa, Japan , Kanagawa (Japan)
  • 2 Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan , Fukuoka (Japan)
  • 3 Hyogo College of Medicine, Division of Lower Gastroenterology, Department of Internal Medicine, Nishinomiya, Japan , Nishinomiya (Japan)
  • 4 Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, 35 Shinano-machi Shinjuku, Tokyo, 160-8582, Japan , Tokyo (Japan)
  • 5 Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan , Tokyo (Japan)
Published Article
Journal of Gastroenterology
Springer Japan
Publication Date
Oct 23, 2012
DOI: 10.1007/s00535-012-0673-1
Springer Nature


Crohn’s disease is a disorder of unknown etiology and complicated pathogenesis. A substantial amount of evidence has accumulated recently and has been applied to clinical practice. The present guidelines were developed based on recent evidence and the formal consensus of experts relevant to this disease. Here we provide an overview of these guidelines, as follows.Target disease: Crohn’s disease Users: Clinical practitioners in internal medicine, surgery, gastroenterology, and general practicePurpose: To provide appropriate clinical indicators to practitionersScope of clinical indicators: Concept of Crohn’s disease, epidemiology, classifications, diagnosis, treatment, follow up, and special situationsIntervention: Diagnosis (interview, physical examination, clinical laboratory tests, imaging, and pathology) and treatment (lifestyle guidance, drug therapy, nutritional therapy, surgery, etc.)Outcome assessment: Attenuation of symptoms, induction and maintenance of remission, imaging findings, quality of life (QOL), prevention of complications and harm of therapyMethods for developing these guidelines: Described in the textBasis of recommendations: Integration of evidence level and consensus of expertsCost-benefit analysis: Not implementedEvaluation of effectiveness: Yet to be confirmedStatus of guidelines: Updated version of the first Guidelines published in 2010Publication sources: Printed publication available and electronic information in preparationPatient information: Not availableDate of publication: October 2011 These guidelines were intended primarily to be used by practitioners in Japan, and the goal of these guidelines is to improve the outcomes of patients with Crohn’s disease.

Report this publication


Seen <100 times